Frontage Announces Expansion of Business in Canada with New Leadership
Frontage Announces Expansion of Business in Canada with New Leadership |
| [01-July-2025] |
EXTON, Pa., July 1, 2025 /PRNewswire/ -- As part of the strategy in expanding service offerings across the globe, Frontage Holdings Corporation is pleased to announce the appointment of Dr. Abdul Mutlib as the President of Frontage Laboratories, Canada. Dr. Mutlib will spearhead Frontage's growth in the Canadian market as he continues to serve as the Chief Scientific & Strategy Officer for Frontage Laboratories. Dr. Mutlib will have an oversight of the Canadian operations based in Toronto and Vancouver. He will report to Co-Chief Executive Officer Dr. Wentao Zhang.
Dr. Mutlib brings more than 35 years of R&D experience in large pharmaceutical and CRO and will play a key role in establishing Frontage as a key partner and service provider to the rapidly growing biotech industry across Canada. This appointment reflects Frontage's commitment to enhancing and expanding its services as a leading global pharmaceutical CRO. Dr. Zhang commented, "Abdul's leadership and experience has been vital to Frontage's growth over the last several years. His vision and strong leadership qualities will drive our success and expansion in Canada." Dr. Mutlib expressed, "I'm deeply honored by this opportunity. I have full confidence in our Canadian team, and together, we aim to expand our services and significantly grow the business in the coming years. I'm excited to collaborate with Canadian authorities and establish Frontage as a leading provider of comprehensive, high-quality R&D services, supporting Canada's vision to become a dynamic hub for biotechnology and pharmaceutical innovation." About Frontage (www.frontagelab.com) Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiaries, including Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) that provides integrated, science-driven, product development services from drug discovery to late-phase clinical process to enable biopharmaceutical companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment, and early-phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions. For more details visit www.frontagelab.com. Media Contact:
SOURCE Frontage Laboratories, Inc. | ||
Company Codes: HongKong:1521, OTC-PINK:FTHCY |
View original content to download multimedia:
